Get the Stockscreener App
125.89
2.70%
3.315
Palvella Therapeutics Inc stock is traded at $125.89, with a volume of 74,375.
It is up +2.70% in the last 24 hours and down -16.75% over the past month.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
See More
Previous Close:
$122.58
Open:
$123.58
24h Volume:
74,375
Relative Volume:
0.30
Market Cap:
$1.81B
Revenue:
$1.30M
Net Income/Loss:
$-49.30M
P/E Ratio:
-30.20
EPS:
-4.1688
Net Cash Flow:
$-29.10M
1W Performance:
-4.15%
1M Performance:
-16.75%
6M Performance:
-2.13%
1Y Performance:
+64.98%
1-Day Range:
$122.51
$127.72
1-Week Range:
$120.27
$139.86
52-Week Range:
$68.96
$161.38
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Name
Palvella Therapeutics Inc
Sector
Industry
Phone
(484) 253-1461
Address
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
125.89 | 1.81B | 1.30M | -49.30M | -29.10M | -4.1688 |
VRTX
Vertex Pharmaceuticals Inc
|
509.86 | 129.23B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.75 | 94.92B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.00 | 82.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.32 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.60 | 42.04B | 5.76B | 514.49M | 1.10B | 4.4813 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-21-26 | Resumed | Chardan Capital Markets | Buy |
| May-12-26 | Initiated | Stephens | Overweight |
| Jan-07-26 | Initiated | Mizuho | Outperform |
| Dec-05-25 | Initiated | BTIG Research | Buy |
| Dec-04-25 | Initiated | Craig Hallum | Buy |
| Nov-19-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-09-25 | Initiated | Oppenheimer | Outperform |
| Aug-06-25 | Initiated | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Apr-09-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-26-25 | Initiated | Stifel | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-20-25 | Initiated | Canaccord Genuity | Buy |
| Feb-05-25 | Initiated | TD Cowen | Buy |
| Dec-26-24 | Initiated | H.C. Wainwright | Buy |
| Dec-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-30-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-19 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Initiated | Jefferies | Buy |
| Jan-16-18 | Reiterated | H.C. Wainwright | Buy |
| May-30-17 | Initiated | Rodman & Renshaw | Buy |
| Aug-05-16 | Resumed | ROTH Capital | Buy |
| Aug-12-15 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-15 | Initiated | Oppenheimer | Outperform |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
View All
Palvella Therapeutics Inc Stock (PVLA) Latest News
Palvella Therapeutics (PVLA) COO sells 4,302 shares under 10b5-1 plan - Stock Titan
Palvella (NASDAQ: PVLA) officer plans new stock sale after three recent trades - Stock Titan
Palvella Therapeutics director George M Jenkins sells $4.17 million in shares By Investing.com - Investing.com South Africa
Palvella Therapeutics director George M Jenkins sells $4.17 million in shares - Investing.com Canada
Director at Palvella Therapeutics (PVLA) sells 27,500 shares under trading plan - Stock Titan
Palvella Therapeutics director George M Jenkins sells $4.17 million in shares - Investing.com
Director at Palvella Therapeutics (NASDAQ: PVLA) plans multi-million-dollar stock sale - Stock Titan
Mizuho Securities Keeps Their Buy Rating on Palvella Therapeutics (PVLA) - theglobeandmail.com
Palvella Therapeutics Names James Treat Chief Medical Officer Ahead of QTORIN Commercialization - citybiz
Palvella at Cantor global healthcare conference: rare-disease push By Investing.com - Investing.com India
Palvella at Cantor global healthcare conference: rare-disease push By Investing.com - Investing.com Canada
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer - Yahoo Finance
KIRITSY CHRISTOPHER P Executes Palvella Therapeutics Options and Sells Shares at $157 on September 2, 2026 - Kalkine Media
Palvella CEO to Pitch Rare-Disease Pipeline at Investor Meets - MyChesCo
Palvella Therapeutics, Inc (NASDAQ: PVLA) Share Price, PVLA Stock News, PVLA Share Price & Updates - Kalkine
ICYMI: Palvella Seeks FDA Approval for Rare-Disease Skin Therapy - MyChesCo
Palvella Therapeutics (NASDAQ: PVLA) director exercises options, then sells 313 shares - Stock Titan
Palvella Therapeutics (NASDAQ: PVLA) investor to sell 375 shares - Stock Titan
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences - The Manila Times
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences - GlobeNewswire
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences - markets.businessinsider.com
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX) - theglobeandmail.com
Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240 - Moomoo
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations - Barchart.com
86% of trial completers aged 6+ were much or very much improved - Stock Titan
36,259 Shares in Palvella Therapeutics, Inc. $PVLA Purchased by Blue Owl Capital Holdings LP - MarketBeat
Palvella Therapeutics COO Kathleen Goin Executes Stock Option Exercises and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) COO Sells $654,807.42 in Stock - MarketBeat
Palvella Therapeutics (NASDAQ: PVLA) COO sells 4,302 shares under 10b5-1 plan - Stock Titan
Palvella Therapeutics, Inc (NASDAQ: PVLA) Share Price, PVLA Stock News, PVLA Share Price & Updates - kalkine.ca
Palvella (PVLA) Latest Quarter: EPS Comes in Below Forecast in the Available Record; Share Response: Shares Fall 6.03% for the Current SessionConsensus Forecast Report - vinanet.vn
Lisanti Capital Growth LLC Purchases Shares of 42,975 Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics (NASDAQ: PVLA) officer plans $647K share sale - Stock Titan
Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel - Seeking Alpha
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands - MarketBeat
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands - TradingView
PRUDENTIAL FINANCIAL INC Establishes New Position in Palvella Th - GuruFocus
Palvella Therapeutics (PVLA): BVF group discloses 4.7% ownership stake in 13G/A - Stock Titan
First Light Asset Management (PVLA) discloses 5.34% Palvella Therapeutics stake in client accounts - Stock Titan
Palvella at Canaccord Genuity’s 46th Annual Growth Conference: launch prep By Investing.com - Investing.com Canada
Palvella (PVLA) Q2 2026 Earnings Call Transcript - AOL.com
Palvella (PVLA) Q2 2026 Earnings Call Transcript - theglobeandmail.com
Prudential Financial (PVLA) reports 6.7% beneficial ownership in Palvella Therapeutics - Stock Titan
Palvella Therapeutics, Inc. (PVLA) stock price, news, quote and history - Yahoo Finance Australia
Palvella Therapeutics, Inc. (PVLA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Palvella Therapeutics, Inc. $PVLA Shares Purchased by The Manufacturers Life Insurance Company - MarketBeat
Is Palvella Therapeutics (PVLA) Fully Valued Ahead Of QTORIN Approval? - Yahoo Finance
Jennison Associates Expands Palvella Therapeutics (PVLA) Stake i - GuruFocus
Palvella Therapeutics Inc (PVLA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Palvella Therapeutics Inc Stock (PVLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Palvella Therapeutics Inc Stock (PVLA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Goin Kathleen | Officer |
Sep 16 '26 |
Proposed Sale |
151.22 |
4,302 |
650,548 |
0 |
| Goin Kathleen | Chief Operating Officer |
Sep 16 '26 |
Option Exercise |
8.11 |
4,302 |
34,883 |
4,302 |
| Goin Kathleen | Chief Operating Officer |
Sep 16 '26 |
Sale |
152.24 |
4,302 |
654,923 |
0 |
| JENKINS GEORGE M | Director |
Sep 15 '26 |
Sale |
150.14 |
1,777 |
266,806 |
160,116 |
| JENKINS GEORGE M | Director |
Sep 14 '26 |
Sale |
151.96 |
13,352 |
2,028,905 |
161,893 |
| JENKINS GEORGE M | Director |
Sep 11 '26 |
Proposed Sale |
150.39 |
27,500 |
4,135,725 |
0 |
| JENKINS GEORGE M | Director |
Sep 11 '26 |
Sale |
151.28 |
12,371 |
1,871,435 |
175,245 |
| KIRITSY CHRISTOPHER P | Director |
Sep 02 '26 |
Option Exercise |
127.20 |
313 |
39,814 |
563 |
| KIRITSY CHRISTOPHER P | Director |
Sep 02 '26 |
Sale |
157.00 |
313 |
49,141 |
250 |
| CHRISTOPHER KIRITSY | Director |
Sep 02 '26 |
Proposed Sale |
157.00 |
375 |
58,875 |
0 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):